fda glp-1 compounding crackdown news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our The FDA is drawing a

Viagra helps blood flow

Several state Medicaid programs cover obesity treatment (California, Pennsylvania, plus ~12 others)

That's why producers may run into formulation hurdles when adding these functional ingredients

Systemic Mast Cell Activation Disease: The Role of Molecular Genetic Alterations in Pathogenesis, Heritability and Diagnostics. Immunology, vol

255,256 Replacing the phosphate backbone by other group improves target affinity, nuclease resistance, and pharmacokinetic properties of nucleic acids

Compared to the placebo (-4.0), liraglutide resulted in a greater change in BMI as a percentage of the 95th percentile (-14.0), and an estimated treatment difference of 10.0 (95% CI, 15.1 to 4.8) was observed